Bölümler
-
Moshe Ornstein, MD, MA, a Genitourinary Medical Oncologist joins the Cancer Advances podcast to talk about intermittent therapy for metastatic renal cell carcinoma (mRCC). Listen as Dr. Ornstein explores the evolution of treatment options, from cytokine and targeted therapies to immunotherapy, and as he delves into the promising concept of treatment breaks to improve patient outcomes.
-
Medical Oncologist in the Lymphoid Malignancies Division, Taylor Brooks, MD, joins the Cancer Advances podcast to discuss real-world data on bispecific antibodies for relapsed or refractory large B-cell lymphomas that was presented at the 2024 American Society of Hematology (ASH) Annual Meeting. Listen as Dr. Brooks shares insights into efficacy, safety, and challenges patients face outside clinical trial parameters, and how these therapies are reshaping treatment approaches.
-
Eksik bölüm mü var?
-
Lukas Nystrom, MD, Orthopaedic Oncology Surgeon and a Co-Director of the Sarcoma Program at Cleveland Clinic joins the Cancer Advances Podcast to talk about the advancements in custom 3D-printed implants for pelvic sarcoma reconstruction. Listen as Dr. Nystrom explains how these personalized implants are transforming sarcoma care by enhancing precision during tumor resections, offering tailored solutions for complex pelvic reconstructions and improving patient outcomes.
-
Ruth Keri, PhD, Associate Director for Basic Research at Case Comprehensive Cancer Center and Professor of Cancer Biology at Cleveland Clinic, returns to the Cancer Advances Podcast to share the latest advancements in targeting YES1 protein to treat triple-negative breast cancer (TNBC). Listen as Dr. Keri discusses how YES1 impacts chemotherapy resistance, tumor growth, and EGFR inhibition, uncovering promising therapeutic opportunities and the potential clinical trials to improve outcomes for patients facing this aggressive cancer.
-
The Cancer Advances podcast is joined by Director of Pediatric Radiation Oncology, Erin Murphy, MD, and resident physician, Jenna Kocsis, MD, to share their latest findings on the use of stereotactic body radiation therapy (SBRT) to treat recurrent osteosarcoma. Listen as they discuss the challenges of managing this radio-resistant tumor, including its use in complex cases involving the spine and epidural space, and explore emerging techniques that have the potential to transform cancer care for young patients while reducing long-term side effects.
-
Theresa Callard-Moore, PhD, LSW, a psychotherapist and certified sex therapist at Cleveland Clinic, joins the Cancer Advances podcast to shed light on the often-overlooked topic of sexual health in cancer patients. In this episode, Dr. Callard-Moore emphasizes the importance of initiating open conversations about sexual health early in the care journey. She also shares valuable insights, practical strategies, and resources to help patients feel heard and supported to address their concerns.
-
Ali Azka, MD, medical oncologist specializing in breast cancer joins the Cancer Advances podcast to talk about her new research on ESR1 mutations and the PI3-kinase pathway's impact on the effectiveness of elacestrant in treating advanced hormone receptor-positive, HER2-negative breast cancer. This study, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), highlights the role of real-world data, optimal treatment sequencing, and the evolving landscape of targeted therapies. Tune in as Dr. Azka explores these advancements and their potential to improve patient outcomes.
-
Chair of the Department of Colorectal Surgery, Director of the Weiss Center for Hereditary GI Neoplasia and Center for Young Onset Colorectal Cancer, David Liska, MD, joins the Cancer Advances Podcast to discuss Cleveland Clinic's integrated program for young people with cancer. Listen as Dr. Liska explains the rise in early-onset cancers, potential factors, and the unique challenges young patients face. Learn how this comprehensive program leverages multidisciplinary care, advanced research, and innovative technology to improve outcomes and survivorship for young cancer patients.
-
Beth Faiman, PhD, CNP, a Nurse Practitioner and Clinical Researcher at Cleveland Clinic specializing in multiple myeloma, joins the Cancer Advances podcast to discuss updates in managing relapsed and refractory multiple myeloma. Listen as Dr. Faiman talks about advancements in treatment, including proteasome inhibitors, monoclonal antibodies, and bispecific antibodies, which improve both survival rates and the quality of life for patients. She also highlights key research presented at the International Myeloma Society meeting, focusing on CAR T-cell therapy, transplant eligibility criteria, and personalized treatment planning.
-
Michael Kelly, MD, PhD, a pediatric hematologist and oncologist at Cleveland Clinic Children's, joins the Cancer Advances podcast to discuss innovative care for vascular anomalies. In this episode, Dr. Kelly explains how they are exploring advanced treatments, including clinical trials using cancer medications to address these non-cancerous conditions, the impact of somatic mutations, and the evolving role of genetic research. Discover the latest advances and how these efforts aim to improve both the quality of life and outcomes for patients facing these rare and challenging conditions.
-
Inpatient Director of the Cellular and Immunotherapy Service, John Molina, MD, EdM, joins the Cancer Advances podcast to talk about the launching of the Cellular and Immunotherapy Service to manage the growing number of patients receiving cellular therapies like CAR-T and bispecific antibodies. Listen as Dr. Molina share insights on the protocols that help identify and mitigate toxicities early, reducing ICU stays and enhancing patient outcomes with the long-term goal of transitioning more patients to outpatient management where possible.
-
Josephine K. Dermawan, MD, PhD, a soft tissue pathologist at Cleveland Clinic joins the Cancer Advances podcast to discuss the development of novel genomic risk stratification models for soft tissue and uterine leiomyosarcomas. Given the complexity and variety of sarcomas, accurately identifying subtypes is key to effective treatment. Listen as Dr. Dermawan explains the challenges of risk stratification and how genomic profiling enhances our ability to predict tumor behavior, leading to more precise treatment decisions.
-
Chair of the Department of Gastroenterology, Hepatology and Nutrition, Michelle Kang Kim, MD, PhD, joins the Cancer Advances podcast to discuss neuroendocrine tumors and carcinoid heart disease. Listen as Dr. Kim shares her expertise on this rare but increasingly prevalent type of cancer, the complexities of managing carcinoid heart disease, a condition seen in patients with metastatic neuroendocrine tumors, and the benefits of multidisciplinary care in treatment planning.
-
Breast Medical Oncologist, Erin Roesch, MD, joins the Cancer Advances podcast to discuss endocrine therapy for breast cancer in young patients. Listen as Dr. Roesch explains the key differences in treatment for premenopausal women, including the use of tamoxifen, ovarian suppression, and aromatase inhibitors.
-
Joshua Arbesman, MD, Dermatologist and Director of the Pigmented Lesion Clinic at Cleveland Clinic, joins the Cancer Advances podcast to talk about the genetic risks of melanoma. Listen as Dr. Arbesman delves into the inherited predispositions for melanoma, highlights key findings from his research on identifying high-risk patients and explains how genetic testing can help in early detection and personalized treatment.
-
Zeina Nahleh, MD, Cancer Center Director and Regional Chair of Hematology Oncology at Cleveland Clinic in Florida joins the Cancer Advances Podcast to discuss the latest breakthroughs in treating brain metastasis in breast cancer patients. Listen as Dr. Nahleh shares insights into the challenges of managing this complex condition, highlights key findings from her recent study, and emphasizes the critical role of combining local and systemic therapies. Discover what the future holds with emerging treatments and how they may improve patient outcomes in this evolving field.
-
Gregory Videtic, MD, Director of the Thoracic Radiation Oncology Program at Cleveland Clinic, joins the 200th episode of the Cancer Advances podcast to talk about neuroprotection in patients with small cell lung cancer. Listen as Dr. Videtic explains the findings of the NRG CC003 trial, which examined how hippocampal-sparing radiation could minimize memory-related side effects while maintaining cancer control.
-
The Cancer Advances podcast is joined by Ofer Reizes, PhD, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research, and Roberto Vargas, MD, Gynecologic Oncologist and Program Director for the Gynecologic Oncology Fellowship to discuss their research on targeting CD55 to combat chemoresistance in ovarian cancer patients. Listen as they insights into the mechanisms behind chemoresistance, the challenges it presents in treatment, and the potential for innovative therapies to transform patient outcomes.
-
Arun D. Singh, MD, Director of Ophthalmic Oncology at Cleveland Clinic Cole Eye Institute, returns to the Cancer Advances podcast to discuss iris melanoma. Listen as Dr. Singh talks about the unique characteristics of this rare eye cancer, the latest advancements in diagnosis and treatment, including cutting-edge imaging techniques and the potential of machine learning. Tune in for this insightful discussion on this rare type of melanoma.
-
The Cancer Advances podcast is joined by third-year internal medicine resident, Heya Batah, MD, and hematologist and medical oncologist, Moaath Khader Mustafa Ali, MD, MPH to discuss the latest findings on the combination of atezolizumab with carboplatin and etoposide in treating extensive stage small cell lung cancer. Listen as they talk about the real-world data presented by Dr. Batah at ASCO, focusing on the impact of atezolizumab on overall survival and progression-free survival compared to traditional chemotherapy alone.
- Daha fazla göster
